Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why MannKind Stock Is Crushing It Today

TheMotleyFool

0 0

Shares of MannKind Corporation (NASDAQ: MNKD) were soaring 13% higher as of 3:32 p.m. EDT on Monday. The big jump came after the company presented new data from clinical studies for inhaled insulin product Afrezza at the American Diabetes Association's 80th Scientific Sessions conference.

MannKind had good news all around at the ADA's virtual conference. The company presented a post hoc analysis from four studies that evaluated Afrezza in patients with Type 1 diabetes. This analysis showed that Afrezza can be safely and effectively dosed at 1.5 to two times the level of injected mealtime insulin.

Image source: Getty Images.

Source Fool.com

Like: 0

UNKNOWN

Share